Oral clindamycin causing acute cholestatic hepatitis without ductopenia: a brief review of idiosyncratic drug-induced liver injury and a case report

Clindamycin is a lincosamide antibiotic active against most of the anaerobes, protozoans, and Gram-positive bacteria, including community-acquired methicillin-resistant Staphylococcus aureus. Its use has increased greatly in the recent past due to wide spectrum of activity and good bioavailability i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of community hospital internal medicine perspectives 2015-01, Vol.5 (5), p.28746-28746
Main Authors: Moole, Harsha, Ahmed, Zohair, Saxena, Nibha, Puli, Srinivas R., Dhillon, Sonu
Format: Article
Language:English
Subjects:
acute cholestatic hepatitis
acute liver failure
Bile
clindamycin
Colleges & universities
drug-induced liver injury
Hepatitis
hepatotoxicity
Liver
Review
Rodents
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clindamycin is a lincosamide antibiotic active against most of the anaerobes, protozoans, and Gram-positive bacteria, including community-acquired methicillin-resistant Staphylococcus aureus. Its use has increased greatly in the recent past due to wide spectrum of activity and good bioavailability in oral form. Close to 20% of the patients taking clindamycin experience diarrhea as the most common side effect. Hepatotoxicity is a rare side effect. Systemic clindamycin therapy has been linked to two forms of hepatotoxicity: transient serum aminotransferase elevation and an acute idiosyncratic liver injury that occurs 1-3 weeks after starting therapy. This article is a case report of oral clindamycin induced acute symptomatic cholestatic hepatitis and a brief review of the topic.
ISSN:2000-9666
2000-9666
DOI:10.3402/jchimp.v5.28746